Last updated: February 27, 2026
What is the Drug Identified by NDC 62756-0533?
The National Drug Code (NDC) 62756-0533 corresponds to Moxetumomab pasudotox-tdfk (Lumoxiti), a recombinant immunotoxin approved by the U.S. Food and Drug Administration (FDA) in September 2018. Lumoxiti is indicated for relapsed or refractory hairy cell leukemia (HCL) in adult patients who have received at least two prior systemic therapies.
Current Market Landscape
Target Population
- Prevalence of Hairy Cell Leukemia: Approximately 600 new cases annually in the U.S.
- Refractory Cases: About 10–15% of HCL patients do not respond to first-line therapy.
- Estimated Patients Eligible for Lumoxiti: 60–90 per year.
Competitive Landscape
- Existing Treatments: Cladribine, pentostatin, and interferon alpha.
- Lumoxiti's Unique Selling Proposition: FDA approval marked the first targeted immunotoxin treatment for HCL, offering an alternative for patients with relapsed/refractory disease.
Use Patterns
- Prescriptions are expected to initiate largely within specialty oncology clinics.
- Adoption in clinical practice has been gradual due to its novel mechanism and costs.
Market Penetration and Sales Trends
Sales Data (Past 3 Years)
| Year |
Estimated Sales (USD million) |
Notable Factors |
| 2020 |
25 |
Low initial adoption, limited awareness. |
| 2021 |
50 |
Increased recognition, marketing efforts, early adoption. |
| 2022 |
78 |
Growing familiarity, broader prescribing base. |
Forecasted Sales (Next 5 Years)
| Year |
Projected Sales (USD million) |
Assumptions |
| 2023 |
102 |
Extended coverage, increased prescribing. |
| 2024 |
125 |
Expanded indication awareness, improved reimbursement. |
| 2025 |
150 |
Saturation nearing, stable demand. |
| 2026 |
170 |
Market stabilizes, dose optimization. |
| 2027 |
190 |
Steady growth, minor competition impact. |
Price Projections and Cost Considerations
Current Pricing
- List Price: Approximately $112,500 per treatment cycle (per FDA label). One cycle typically involves 3 infusions over 28 days.
- Average Wholesale Price (AWP): Slightly higher than list, around $125,000 per cycle.
- Net Price: Post discounts, rebates, and negotiations, estimated to be $100,000–$112,500.
Cost Factors Influencing Future Prices
- Manufacturing Complexity: Recombinant immunotoxins require specialized bioprocessing.
- Market Dynamics: Increased competition from emerging therapies could pressure prices downward.
- Reimbursement Trends: Payer negotiations and value-based arrangements may influence final prices.
- Pricing Trends of Similar Biologics: Similar immunotherapies range from $80,000 to $150,000 per course.
Price Projection Factors
- Expected to remain within the current range ($100,000–$125,000 per treatment cycle).
- Slight decreases may occur due to market competition and biosimilar entry, although no biosimilar is currently approved for this drug.
- Potential for value-based pricing based on patient outcomes and treatment durability.
Regulatory and Policy Impact
- Reimbursement: Centers for Medicare & Medicaid Services (CMS) and private payers could negotiate pricing based on clinical value.
- Pricing Caps: Discussion of caps or value-based agreements may influence future prices.
- Global Markets: Limited approval outside the U.S.; pricing in Europe and Asia could differ significantly due to different healthcare systems.
Overall Commercial Outlook
- NDC 62756-0533 (Lumoxiti) remains a niche product with a small but steady growth trajectory.
- Market size constrained by the rare disease status.
- Price stability expected unless significant breakthroughs or biosimilars emerge.
Key Takeaways
- Lumoxiti targets a narrow patient population with relapsed/refractory hairy cell leukemia.
- Sales have grown modestly, reflecting its niche status.
- Pricing remains high, around $100,000–$125,000 per treatment cycle, with limited downward pressure in the near term.
- Growth is driven by increased clinical adoption, improved awareness, and payer acceptance.
- Market expansion outside the U.S. is unlikely in the near term due to regulatory hurdles.
FAQs
1. What factors could significantly change the price of Lumoxiti?
Introduction of biosimilars, shifts in payer negotiations, or new competing therapies could reduce the price.
2. How does the treatment cycle length affect the total cost?
Each cycle costs approximately $112,500; multiple cycles increase total expenditure proportionally.
3. What is the role of reimbursement policies in market penetration?
Reimbursement determines access; favorable policies can accelerate adoption, influencing sales and prices.
4. Are there plans for new indications or expanded use?
Currently, no FDA-approved additional indications exist; expanded use could increase the patient base.
5. How does the rarity of hairy cell leukemia impact the market for Lumoxiti?
The small patient population limits market size but allows high pricing due to lack of alternatives.
References
- U.S. Food and Drug Administration (2018). Lumoxiti prescribing information.
- IQVIA. (2022). Biopharmaceutical sales data.
- FDA. (2018). FDA approval letter for Lumoxiti.
- EvaluatePharma. (2022). Biologics market forecast.
- Centers for Medicare & Medicaid Services. (2023). Reimbursement policies.
